Editor's note: There are many fallen leaves in the garden, and I feel sad that I have known that I have fallen. In this issue, the editor-in-chief of the literature recommendation column for intestinal cancer - , Second Affiliated Hospital of Zhejiang University School of Medicine , Professor Yuan Ying, conducted relevant literature recommendations in the field of intestinal cancer. Women showed their "ying" posture and went to a thought agreement for exchanges.
First phase
Engineering
Engineering Professor Yuan Ying strongly recommended
Dr. Chen Jiaqi translated: "Tumor immunogenomic characteristics determine the prognosis of standard combination treatment of bevacizumab and cetuximab in patients with metastatic colorectal cancer"
Expert introduction
Yuan Ying Professor
Director of Internal Medicine, PhD, Chief Physician, Doctor of Oncology, Second Affiliated Hospital of Zhejiang University School of Medicine,
Deputy Director of Key Laboratory of Malignant Tumor Warning and Intervention of Ministry of Education
Executive Deputy Editor-in-Chief Editor and Editorial Department Director
Standing Committee Member of Colorectal Cancer Professional Committee of China Anti-Cancer Association and Leader of Genetics Group
Member of the Tumor Targeted Therapy Professional Committee of China Anti-Cancer Association
Member of the Metastatic Professional Committee of China Anti-Cancer Association
Member of the Metastatic Professional Committee of China Anti-Cancer Association
Director of China Clinical Tumor Association (CSCO)
Chen Jiaqi Doctor
Doctor of Oncology Medicine (M.D.), Second Affiliated Hospital of Zhejiang University School of Medicine, Deputy Chief Physician
Graduated from Beijing Union Medical College 8-year
Youth Committee Member of the Integrated Oncology Branch of the Chinese Anti-Cancer Association
Secretary of Colorectal Cancer Youth Committee of Zhejiang Anti-Cancer Association Colorectal Cancer Youth Committee
China Medical and Health Culture Association
National Health Literacy Promotion Branch Youth Committee Member of the Youth Committee of the Chinese Anti-Cancer Association
High School of Health and Health Promotion Branch
High School of Health and Literacy Promotion Branch
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of Health and Human Resources
High School of the Chinese Anti-Cancer Association
High School of Health and Human Resources
High School of the Chinese Anti-Cancer Association
High School of the Chinese Anti-Cancer Association
High School of the Chinese Anti-Cancer Association
High School of the Chinese Anti-Cancer Association
H The 80405 study is a randomized phase III clinical study of the first-line use of bevacizumab or cetuximab combined with chemotherapy for metastatic colorectal cancer. This study evaluated its effect on overall survival (OS) by detecting the tumor immunologic characteristics of enrolled cases in this clinical study.
Method
This study performed RNA sequencing of primary lesions in 554 cases. Immune characteristics such as macrophage , lymphocyte , TGFβ, IFNγ, wound healing and cytotoxicity were evaluated. Naive and memory B cells, plasma cells , CD8+ T cells, resting and memory activated CD4+ T cells , M0 and M2 macrophages, and activated mast cells were evaluated using the CIBERSORTx scoring system.
Results
study found that higher M2 macrophage scores [HR: 6.30; 95% confidence interval (CI), 3.0-12.15] and TGF β-specific expression (HR, 1.35; 95% CI, 1.05-1.77) were associated with OS decline. The higher plasma cell score (HR, 0.55; 95% CI, 0.38-0.87) was associated with memory-activated CD4+ T cell score and OS enhancement. Using the optimal cutoff values for these four characteristic parameters, the patient's OS-associated scores can be set to 4, 3, 2, or 0-1, with the corresponding median OS changes of 42.5 (35.8-47.8), 31.0 (28.8-34.4), 25.2 (20.6-27.9), and 17.7 (13.5-20.4) months, respectively.
Explain that
new immune profile typing can further evaluate and improve the patient's response level to treatment. And they will provide the rationale for more effective immunotherapy strategies.
Editor's comment
This study is based on the classic 80405 study, typing the immunogenomics of the cases, and clarifying that the specific expression of M2 macrophages and TGF β in them is negatively correlated with the efficacy, and is positively correlated with plasma cell levels and memory-activated CD4+ T cells. The results of this study are more targeted in patients receiving traditional chemotherapy combined with antivascular therapy or antiepidermal growth factor therapy, rather than the more prevalent immunotherapy results. Therefore, the significance of these four factors in all patients with colorectal cancer can be explained. At present, except for colorectal cancer patients with dMMR/MSI-H, treatment based on immune checkpoint inhibitors has little effect on more colorectal cancer patients with pMMR/MSS. The results of this study provide more possibilities for the application of immunotherapy in all patients with colorectal cancer in terms of phenotype, but more basic research mechanisms and clinical research data are still needed.
Copyright Statement
Copyright of this article belongs to Yiyuehui.Welcome to forward and share. If any other media needs to reprint or quote all copyrighted content on this website, they must obtain authorization and indicate "Reprinted from: Yiyuehui" in a conspicuous location.
